FY2024 Earnings Estimate for NeuroPace, Inc. (NASDAQ:NPCE) Issued By Cantor Fitzgerald

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for NeuroPace in a research report issued on Wednesday, August 14th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($1.08) per share for the year, up from their previous estimate of ($1.14). Cantor Fitzgerald has a "Overweight" rating and a $18.00 price target on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.14) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to analysts' expectations of $18.30 million. NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. The company's quarterly revenue was up 16.6% on a year-over-year basis. During the same period last year, the company earned ($0.36) earnings per share.

A number of other equities analysts also recently commented on the company. Morgan Stanley cut their price objective on NeuroPace from $9.50 to $8.00 and set an "equal weight" rating on the stock in a report on Monday, July 15th. Wells Fargo & Company cut their price target on shares of NeuroPace from $20.00 to $15.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $14.00.

NeuroPace Trading Up 3.3 %

Shares of NPCE stock traded up $0.23 on Monday, reaching $7.10. 37,375 shares of the stock were exchanged, compared to its average volume of 108,825. NeuroPace has a 1-year low of $4.40 and a 1-year high of $18.15. The stock has a market cap of $204.25 million, a P/E ratio of -5.97 and a beta of 1.80. The company has a quick ratio of 5.56, a current ratio of 6.43 and a debt-to-equity ratio of 4.05. The firm has a 50 day moving average of $7.17 and a two-hundred day moving average of $10.75.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Hillsdale Investment Management Inc. purchased a new position in NeuroPace in the first quarter valued at about $155,000. Rhumbline Advisers acquired a new position in shares of NeuroPace in the 2nd quarter valued at approximately $111,000. Financial Advocates Investment Management boosted its stake in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company's stock valued at $113,000 after buying an additional 5,000 shares during the last quarter. XTX Topco Ltd grew its position in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock worth $182,000 after buying an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of NeuroPace in the second quarter worth $257,000. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.